UCLA and Leica Biosystems to collaborate in digital pathology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The UCLA Department of Pathology and Laboratory Medicine and Leica Biosystems will collaborate in digital pathology.

Product testing will be conducted with UCLA to validate digital pathology in a high-volume setting. This joint effort builds upon the existing relationship between UCLA and Leica Biosystems that was established in 2011.

The pathology team at UCLA will be working with Leica Biosystems Aperio ePathology and will test and provide quantitative feedback on current and next-generation products from bench research to full clinical adoption.

YOU MAY BE INTERESTED IN

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login